Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly

Clinical and Experimental Vaccine Research

Volumn 6, Issue 1, 2017, Pages 38-44

  Seo, Yu Bin ^a   Choi, Won Suk ^b   Lee, Jacob ^a   Song, Joon Young ^b,c   Cheong, Hee Jin ^b,c   Kim, Woo Joo ^b,c  

^a Hallym University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Asian Pacific Influenza Institute   (South Korea)

Author keywords

Immunogenicity; Influenza; Pneumococcus; Safety; Vaccine

Indexed keywords

GCFLU; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VACCINATION; INJECTION SITE REACTION; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN REDNESS; SWELLING; VACCINATION REACTION; VACCINE IMMUNOGENICITY;

EID: 85029176464     PISSN: 22873651     EISSN: 2287366X     Source Type: Journal    
DOI: 10.7774/cevr.2017.6.1.38     Document Type: Article

References (19)

1. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010;50:175-83.
2. Grabowska K, Hogberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 2006; 6:58.
3. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004; 190:1-10.
4. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-81.
5. Mooney JD, Weir A, McMenamin J, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008;8:53.
6. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, et al. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010;10:73.
7. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17 Suppl 1:S91-3.
8. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008;26:4284-9.
9. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004;23:363-8.
10. Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011;10:1143-67.
11. Song JY, Cheong HJ, Heo JY, et al. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J 2013;54:469-75.
12. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996;156: 205-8.
13. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine 2011;29:5195-202.
14. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133-8.
15. Song JY, Cheong HJ, Woo HJ, et al. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. J Korean Med Sci 2011;26:191-5.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville: U.S. Department of Health and Human Services; 2007.
17. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 1997;314:1663-5.
18. Frenck RW Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012;19: 1296-303.
19. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 2015;33:4647-52.